Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
AssigneePfizer Inc.
InventorsKazuo Ando, Kiyoshi Kawamura
Life of this patent
Estimating the term…
Abstract
This invention relates to a compound of the formula: 1 or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is NH2; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
Claims20
A compound of the following formula:
- 24
- or a pharmaceutically acceptable salt thereof, wherein
- A is selected from the group consisting of
- a) (5- to 6-membered)-heteroaryl containing 1 to 4 ring heteroatoms independently selected from —N═, —NR′—, —O—, or —S—, wherein said heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- wherein R′ is hydrogen or (C1-C4)alkyl;
- wherein each of said (C1-C4)alkyl may optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- b) (5- to 6-membered)-heteroaryl containing 1 to 2 ring heteroatoms independently selected from the group consisting of —N═, —NR′—, —S— or —O—;
- wherein said heteroaryl is fused to a saturated, partially saturated or aromatic (5- to 7-membered)-carbocyclic ring;
- wherein either of said (5- to 6-membered)-heteroaryl ring or said fused saturated, partially saturated or aromatic (5- to 7-membered)-carbocyclic ring may optionally be substituted with 1 to 2 substituents per ring, wherein said substituents are independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- wherein R′ is hydrogen or (C1-C4)alkyl;
- wherein each of said (C1-C4)alkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- and
- c) (5- to 6-membered)-heteroaryl containing 1 to 2 ring heteroatoms independently selected from the group consisting of —N═, —NR′—, —S—, or —O—;
- wherein said heteroaryl is fused to a (5- to 6-membered)-heteroaryl containing 1 to 2 ring heteroatoms independently selected from the group consisting of —N═, —NR′—, —S— or —O—;
- wherein either of said (5- to 6-membered)-heteroaryl or said fused (5- to 6-membered)-heteroaryl is optionally substituted with one to two substituents per ring, wherein said substituents are independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- wherein R′ is hydrogen or (C1-C4)alkyl;
- wherein each of said (C1-C4)alkyl may optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- R1 is selected from the,group consisting of
- a) (5- to 6-membered)-heteroaryl containing 1 to 4 ring heteroatoms independently selected from —N═, —NR—, —O—, or —S—, wherein said heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- wherein R′ is hydrogen or (C1-C4)alkyl;
- wherein each of said (C1-C4)alkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- b) (5- to 6-membered)-heteroaryl containing 1 to 2 ring heteroatoms independently selected from the group consisting of —N═, —NR′—, —S— or —O—;
- wherein said heteroaryl is fused to a saturated, partially saturated or aromatic (5- to 7-membered)-carbocyclic ring;
- wherein either of said (5- to 6-membered)-heteroaryl ring or said fused saturated, partially saturated or aromatic (5- to 7-membered)-carbocyclic ring is optionally substituted with 1 to 2 substituents per ring, wherein said substituents are independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- wherein R′ is hydrogen or (C1-C4)alkyl;
- wherein each of said (C1-C4)alkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- and
- c) (5- to 6-membered)-heteroaryl containing 1 to 2 ring heteroatoms independently selected from the group consisting of —N═, —NR′—, —S—, or —O—;
- wherein said heteroaryl is fused to a (5- to 6-membered)-heteroaryl containing 1 to 2 ring heteroatoms independently selected from the group consisting of —N═, —NR′—, —S— or —O—;
- wherein either of said (5- to 6-membered)-heteroaryl or said fused (5- to 6-membered)-heteroaryl is optionally substituted with one to two substituents per ring, wherein said substituents are independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amino, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- wherein R′ is hydrogen or (C1-C4)alkyl;
- wherein each of said (C1-C4)alkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, amino, (C1-C4)alkylamino, di[(C1-C4)alkyl]amino, amido, (C1-C4)alkylamido, di[(C1-C4)alkyl]amido, (C1-C4)alkyl-(C═O)—O—, (C1-C4)alkyl-(C═O)—N(R′)—, formyl, (C1-C4)alkyl-(C═O)— and (C1-C4)alkoxy-(C═O)—;
- R2 is NH2;
- R3 and R4 are independently selected from the group consisting of hydrogen, halo, (C1-C4)alkyl, (C2-C4)alkenyl, (C1-C4)alkoxy, (C1-C4)alkyl-(C═O)—, cyano, nitro, carboxy, (C1-C4)alkoxy-(C═O)—, amino-(C═O)—, (C1-C4)alkyl-amino-(C═O)—, di[(C1-C4)alkyl]-amino-(C═O)—, N-[(C1-C4)alkyl]-N-phenyl-amino-(C═O)—, N-[(C1-C4)alkyl]-N-[(5- to 6-membered)-heteroaryl]-amino-(C═O)—, wherein said (5- to 6-)membered heteroaryl contains 1 to 4 heteroatoms independently selected from —N═, —NR′—, —O— and —S—;
- wherein each of said (C1-C4)alkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, cyano, phenyl, (C1-C4)alkoxy and (5- to 6-membered)-heteroaryl containing 1 to 4 heteroatoms independently selected from —N═, —NR′—, —O— and —S—;
- wherein each of said R′ is independently hydrogen or (C1-C4)alkyl;
- and
- X1, X2, X3 and X4 are independently selected from the group consisting of hydrogen, halo, hydroxy, cyano, mercapto, carboxy, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkyl-S—, (C1-C4)alkyl-amino-, di[(C1-C4)alkyl]-amino-, (C1-C4)alkyl-(C═O)—, (C1-C4)alkoxy-(C═O)— and amino-C(═O)—;
- wherein each said (C1-C4)alkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, amino, (C1-C4)alkyl-amino-, di[(C1-C4)alkyl]-amino-, hydroxy, carboxy, amino-(C═O)—, (C1-C4)alkyl-amino-C(═O)—, di[(C1-C4)alkyl]-amino-C(═O)—, mercapto, (C1-C4)alkyl-S— and (C1-C4)alkoxy-(C═O)—.
A pharmaceutical composition for treating a disease or condition selected from the group consisting of diseases or conditions in which prostaglandins are implicated as pathogens, pain, fever, inflammation, rheumatic fever, symptoms associated with influenza and other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis including rheumatoid arthritis, degenerative joint disease or osteoarthritis, gout and ankylosing spondylitis, bursitis, burns, injuries following surgical and dental procedures, disease or conditions associated with cellular neoplastic transformations and metastic tumor growth, cancer, colorectal cancer, breast and skin cancer, familiar adenomatous polyposis, cyclooxygenase-mediated proliferation disorders, cyclooxygenase-mediated proliferation disorders in diabetic retinopathy and tumor angiogenesis, prostaniod-induced smooth muscle contraction mediated by synthesis of contractile prostanoids, dysmenorrhea, premature labor, asthma, eosinophil related disorders, neurodegenerative diseases, Alzheimer's and Parkinson's disease, bone loss, osteoarthritis, peptic ulcers, gastritis, regional enterotis, ulcerative colitis, diverticulitis, recurrent of gastrointestinal lesions, gastrointestinal bleeding, coagulation, anemia, hypoprothrombinemia, haemophilia, bleeding problems;
- kidney disease and conditions prior to surgery of taking of anticoagulants.
Dependencies are inferred from the claim text.